Literature DB >> 22265059

National drug policies to local formulary decisions in Thailand, China, and Australia: drug listing changes and opportunities.

Worasuda Yoongthong1, Shanlian Hu, Jennifer A Whitty, Suwit Wibulpolprasert, Kitti Sukantho, Wannisa Thienthawee, Huixue Han, Paul A Scuffham.   

Abstract

Mesh：

Year:  2012        PMID： 22265059     DOI： 10.1016/j.jval.2011.11.003

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  9 in total

1.  Evaluation of Need and Distribution of National Essential Medicines List in Village Clinics: A Cross-sectional Study Based on the Perspective of Village Doctors in China.

Authors:  Zan Wang; Rui Chang; Yin-Bo Luo; Jing Wu; Qi Wang; Zu-Xun Lu; Jun-An Liu
Journal:  Curr Med Sci       Date:  2019-07-25

Review 2.  A Systematic Review Comparing the Acceptability, Validity and Concordance of Discrete Choice Experiments and Best-Worst Scaling for Eliciting Preferences in Healthcare.

Authors:  Jennifer A Whitty; Ana Sofia Oliveira Gonçalves
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

3.  Uptake of new antidiabetic medications in three emerging markets: a comparison between Brazil, China and Thailand.

Authors:  Christine Y Lu; Isabel Cristina M Emmerick; Peter Stephens; Dennis Ross-Degnan; Anita K Wagner
Journal:  J Pharm Policy Pract       Date:  2015-02-16

Review 4.  A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development.

Authors:  Lianne Barnieh; Fiona Clement; Anthony Harris; Marja Blom; Cam Donaldson; Scott Klarenbach; Don Husereau; Diane Lorenzetti; Braden Manns
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

5.  Policies and programs to facilitate access to targeted cancer therapies in Thailand.

Authors:  Rosarin Sruamsiri; Dennis Ross-Degnan; Christine Y Lu; Nathorn Chaiyakunapruk; Anita K Wagner
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

6.  Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis.

Authors:  Rosarin Sruamsiri; Anita K Wagner; Dennis Ross-Degnan; Christine Y Lu; Teerapon Dhippayom; Surachat Ngorsuraches; Nathorn Chaiyakunapruk
Journal:  BMJ Open       Date:  2016-03-17       Impact factor: 2.692

7.  The Impact of the National Essential Medicines Policy on Rational Drug Use in Primary Care Institutions in Jiangsu Province of China.

Authors:  Jianqian Chao; Jiangyi Gu; Hua Zhang; Huanghui Chen; Zhenchun Wu
Journal:  Iran J Public Health       Date:  2018-01       Impact factor: 1.429

8.  Access to and price trends of antidiabetic, antihypertensive, and antilipidemic drugs in outpatient settings of the Universal Coverage Scheme in Thailand.

Authors:  Chulaporn Limwattananon; Onanong Waleekhachonloet
Journal:  PLoS One       Date:  2019-02-20       Impact factor: 3.240

9.  The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders.

Authors:  Riswandy Wasir; Sylvi Irawati; Amr Makady; Maarten Postma; Wim Goettsch; Talitha Feenstra; Erik Buskens
Journal:  PLoS One       Date:  2019-11-27       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.